Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 18, 2024, titled "Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder (MDD)".